M

Malin Corporation PLC
ISEQ:MLC

Watchlist Manager
Malin Corporation PLC
ISEQ:MLC
Watchlist
Price: 7.95 EUR -0.62% Market Closed
Market Cap: €34.4m

Malin Corporation PLC
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Malin Corporation PLC
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
M
Malin Corporation PLC
ISEQ:MLC
Operating Income
-€2.5m
CAGR 3-Years
10%
CAGR 5-Years
29%
CAGR 10-Years
N/A
ICON PLC
NASDAQ:ICLR
Operating Income
$1.1B
CAGR 3-Years
11%
CAGR 5-Years
23%
CAGR 10-Years
16%
No Stocks Found

Malin Corporation PLC
Glance View

Malin Corp. Plc.invests and supports innovative life sciences companies, which develops exceptional science and technology to deliver transformative outcomes for patients. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The company went IPO on 2015-03-25. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, CG Oncology, Wren, KNOW Bio and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of hematological malignancies, including multiple myeloma, and solid tumours, like prostate cancer. The company is also developing two CAR-T therapies: autologous and allogeneic. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder-saving therapeutics for patients with bladder cancer.

MLC Intrinsic Value
44.73 EUR
Undervaluation 82%
Intrinsic Value
Price €7.95
M

See Also

What is Malin Corporation PLC's Operating Income?
Operating Income
-2.5m EUR

Based on the financial report for Dec 31, 2024, Malin Corporation PLC's Operating Income amounts to -2.5m EUR.

What is Malin Corporation PLC's Operating Income growth rate?
Operating Income CAGR 5Y
29%

Over the last year, the Operating Income growth was 44%. The average annual Operating Income growth rates for Malin Corporation PLC have been 10% over the past three years , 29% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett